多西他赛与紫杉醇在食管癌术后辅助化疗中的安全性分析

多西他赛与紫杉醇在食管癌术后辅助化疗中的安全性分析

曹亮;郭彦伟;王志伟;潘静;刘超;刘艳

【期刊名称】《中国实用医刊》 【年(卷),期】2014(041)007

【摘要】Objective To compare the safety of docetaxel and paclitaxel in the adjuvant chemotherapy of patients with esophageal squamous cell cancer.Methods Eighty-two patients with esophageal squamous cell cancer were randomized divided into two groups.The 42 patients in study group were treated with docetaxel (75 mg/m2)and cisplatin (60 mg/m2)on day 1,every 3 weeks; the 40 cases in control group were treated with paclitaxel (135 mg/m2) and cisplatin (60 mg/m2) on day 1,every

3

weeks.All

patients

received

4-6

courses

of

chemotherapy.Results The KPS (Kamofsky Performance Status) improve rate was 85.7％ and 55.0％ in study group and control group,respectively (P ＜ 0.05).The granulocytopenia and gastrointestinal toxicities in study group were much less than those in control group (P ＜ 0.05).There were no significant differences in the neurotoxicity,liver and kidney toxicity or cardiovascular toxicity between the two groups.There were no delayed medication or adjusted dosage induced by chemotherapy toxicity in the two groups.Conclusions Docetaxel plus cisplatin is superior to paclitaxel plus cisplatin in the adjuvant chemotherapy for patients with esophageal squamous cell cancer in the